| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
DXCM Stock Overview
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.
DexCom Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$77.63 |
| 52 Week High | US$164.86 |
| 52 Week Low | US$66.89 |
| Beta | 1.07 |
| 1 Month Change | 6.06% |
| 3 Month Change | -39.87% |
| 1 Year Change | -28.05% |
| 3 Year Change | 113.24% |
| 5 Year Change | 337.60% |
| Change since IPO | 2,544.97% |
Recent News & Updates
Is It Time To Consider Buying DexCom, Inc. (NASDAQ:DXCM)?
Let's talk about the popular DexCom, Inc. ( NASDAQ:DXCM ). The company's shares saw a double-digit share price rise of...
We Like These Underlying Return On Capital Trends At DexCom (NASDAQ:DXCM)
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...
Shareholder Returns
| DXCM | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.3% | -0.1% | -2.2% |
| 1Y | -28.1% | -24.7% | -21.2% |
Return vs Industry: DXCM underperformed the US Medical Equipment industry which returned -24.7% over the past year.
Return vs Market: DXCM underperformed the US Market which returned -21.2% over the past year.
Price Volatility
| DXCM volatility | |
|---|---|
| DXCM Average Weekly Movement | 8.6% |
| Medical Equipment Industry Average Movement | 10.4% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: DXCM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: DXCM's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 6,300 | Kevin Sayer | https://www.dexcom.com |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
DexCom Fundamentals Summary
| DXCM fundamental statistics | |
|---|---|
| Market Cap | US$30.47b |
| Earnings (TTM) | US$195.50m |
| Revenue (TTM) | US$2.57b |
155.9x
P/E Ratio11.8x
P/S RatioIs DXCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXCM income statement (TTM) | |
|---|---|
| Revenue | US$2.57b |
| Cost of Revenue | US$837.60m |
| Gross Profit | US$1.73b |
| Other Expenses | US$1.54b |
| Earnings | US$195.50m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Jul 28, 2022
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 67.44% |
| Net Profit Margin | 7.60% |
| Debt/Equity Ratio | 89.8% |
How did DXCM perform over the long term?
See historical performance and comparisonValuation
Is DXCM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DXCM?
Other financial metrics that can be useful for relative valuation.
| What is DXCM's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | US$30.47b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 11.6x |
| Enterprise Value/EBITDA | 79.3x |
| PEG Ratio | 5.4x |
Price to Sales Ratio vs Peers
How does DXCM's PS Ratio compare to its peers?
| DXCM PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 6.3x | ||
IDXX IDEXX Laboratories | 9.2x | 10.0% | US$30.1b |
RMD ResMed | 8.9x | 8.6% | US$31.6b |
BAX Baxter International | 2.4x | 5.0% | US$33.0b |
STE STERIS | 4.6x | 7.9% | US$21.1b |
DXCM DexCom | 11.8x | 16.3% | US$30.5b |
Price-To-Sales vs Peers: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the peer average (6.3x).
Price to Earnings Ratio vs Industry
How does DXCM's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Sales vs Industry: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the US Medical Equipment industry average (3.7x)
Price to Sales Ratio vs Fair Ratio
What is DXCM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 11.8x |
| Fair PS Ratio | 9.5x |
Price-To-Sales vs Fair Ratio: DXCM is expensive based on its Price-To-Sales Ratio (11.8x) compared to the estimated Fair Price-To-Sales Ratio (9.5x).
Share Price vs Fair Value
What is the Fair Price of DXCM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DXCM ($77.63) is trading above our estimate of fair value ($72.1)
Significantly Below Fair Value: DXCM is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: DXCM is poor value based on its PEG Ratio (5.4x)
Discover undervalued companies
Future Growth
How is DexCom forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
29.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DXCM's forecast earnings growth (29.1% per year) is above the savings rate (1.9%).
Earnings vs Market: DXCM's earnings (29.1% per year) are forecast to grow faster than the US market (13.6% per year).
High Growth Earnings: DXCM's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: DXCM's revenue (16.3% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: DXCM's revenue (16.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DXCM's Return on Equity is forecast to be low in 3 years time (17.6%).
Discover growth companies
Past Performance
How has DexCom performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
59.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DXCM has high quality earnings.
Growing Profit Margin: DXCM's current net profit margins (7.6%) are lower than last year (26.2%).
Past Earnings Growth Analysis
Earnings Trend: DXCM has become profitable over the past 5 years, growing earnings by 59.3% per year.
Accelerating Growth: DXCM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DXCM had negative earnings growth (-63.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (12.9%).
Return on Equity
High ROE: DXCM's Return on Equity (8.9%) is considered low.
Discover strong past performing companies
Financial Health
How is DexCom's financial position?
Financial Health Score
4/6Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: DXCM's short term assets ($3.7B) exceed its short term liabilities ($711.4M).
Long Term Liabilities: DXCM's short term assets ($3.7B) exceed its long term liabilities ($2.2B).
Debt to Equity History and Analysis
Debt Level: DXCM has more cash than its total debt.
Reducing Debt: DXCM's debt to equity ratio has increased from 27.9% to 89.8% over the past 5 years.
Debt Coverage: DXCM's debt is well covered by operating cash flow (24.7%).
Interest Coverage: DXCM's interest payments on its debt are not well covered by EBIT (2.8x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is DexCom current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DXCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DXCM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DXCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DXCM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DXCM has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
Kevin Sayer (64 yo)
11.08yrs
Tenure
US$11,985,324
Compensation
Mr. Kevin Ronald Sayer has been Executive Chairman of DexCom, Inc. since July 30, 2018. Mr. Sayer has been the Chief Executive Officer of DexCom, Inc. since January 5, 2015 and as its President since June...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD11.99M) is about average for companies of similar size in the US market ($USD13.34M).
Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: DXCM's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
Experienced Board: DXCM's board of directors are considered experienced (8.7 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
DexCom, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: DexCom, Inc.
- Ticker: DXCM
- Exchange: NasdaqGS
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$30.470b
- Shares outstanding: 392.50m
- Website: https://www.dexcom.com
Number of Employees
Location
- DexCom, Inc.
- 6340 Sequence Drive
- San Diego
- California
- 92121
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/07/04 00:00 |
| End of Day Share Price | 2022/07/01 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.